UnitedHealth Group, Eli Lilly and Company, Johnson & Johnson, Hims & Hers Health, Merck & Co., Inc., Gilead Sciences, and AbbVie are the seven Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies operating in the healthcare sector, including pharmaceutical manufacturers, biotechnology firms, medical device producers and healthcare service providers. Investors buy and sell these stocks to gain exposure to the development, production and distribution of medical treatments, diagnostics and equipment. Performance in this sector is often influenced by regulatory approvals, research breakthroughs and demographic trends. These companies had the highest dollar trading volume of any Medical stocks within the last several days.
UnitedHealth Group (UNH)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
UNH traded down $5.16 during trading hours on Friday, reaching $302.04. The company's stock had a trading volume of 16,024,789 shares, compared to its average volume of 7,346,801. UnitedHealth Group has a fifty-two week low of $248.88 and a fifty-two week high of $630.73. The stock has a market cap of $273.99 billion, a PE ratio of 12.65, a P/E/G ratio of 1.42 and a beta of 0.44. The business's 50-day moving average is $359.15 and its 200-day moving average is $462.77. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.85 and a quick ratio of 0.85.
Read Our Latest Research Report on UNH
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
LLY traded down $21.61 during trading hours on Friday, reaching $763.43. The company's stock had a trading volume of 6,197,089 shares, compared to its average volume of 3,668,639. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The stock has a market cap of $723.53 billion, a PE ratio of 62.12, a P/E/G ratio of 1.11 and a beta of 0.40. The business's 50-day moving average is $780.48 and its 200-day moving average is $800.93. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06.
Read Our Latest Research Report on LLY
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
JNJ traded down $0.92 during trading hours on Friday, reaching $149.81. The company's stock had a trading volume of 22,591,152 shares, compared to its average volume of 7,993,824. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The stock has a market cap of $360.44 billion, a PE ratio of 16.66, a P/E/G ratio of 2.27 and a beta of 0.42. The business's 50-day moving average is $154.07 and its 200-day moving average is $153.65. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.
Read Our Latest Research Report on JNJ
Hims & Hers Health (HIMS)
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
HIMS traded up $3.40 during trading hours on Friday, reaching $64.47. The company's stock had a trading volume of 42,122,835 shares, compared to its average volume of 21,595,341. Hims & Hers Health has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The stock has a market cap of $14.43 billion, a PE ratio of 93.44, a P/E/G ratio of 2.42 and a beta of 2.09. The business's 50-day moving average is $48.43 and its 200-day moving average is $39.22.
Read Our Latest Research Report on HIMS
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
MRK traded down $0.05 during trading hours on Friday, reaching $79.24. The company's stock had a trading volume of 33,825,641 shares, compared to its average volume of 13,041,534. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $134.63. The stock has a market cap of $198.98 billion, a PE ratio of 11.53, a P/E/G ratio of 0.82 and a beta of 0.38. The business's 50-day moving average is $78.89 and its 200-day moving average is $88.43. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.41 and a quick ratio of 1.16.
Read Our Latest Research Report on MRK
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
NASDAQ:GILD traded up $0.50 during trading hours on Friday, reaching $108.50. 23,266,621 shares of the stock were exchanged, compared to its average volume of 7,661,575. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The business has a 50-day moving average of $106.16 and a two-hundred day moving average of $102.81. Gilead Sciences has a twelve month low of $66.01 and a twelve month high of $119.96. The company has a market capitalization of $134.97 billion, a price-to-earnings ratio of 22.84, a PEG ratio of 0.70 and a beta of 0.29.
Read Our Latest Research Report on GILD
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE:ABBV traded down $0.33 during trading hours on Friday, reaching $185.16. 12,149,354 shares of the stock were exchanged, compared to its average volume of 6,244,176. The company has a quick ratio of 0.64, a current ratio of 0.76 and a debt-to-equity ratio of 44.14. The business has a 50-day moving average of $185.19 and a two-hundred day moving average of $187.70. AbbVie has a twelve month low of $163.52 and a twelve month high of $218.66. The company has a market capitalization of $327.06 billion, a price-to-earnings ratio of 78.79, a PEG ratio of 1.23 and a beta of 0.50.
Read Our Latest Research Report on ABBV
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider UnitedHealth Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UnitedHealth Group wasn't on the list.
While UnitedHealth Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
